DEF 14A: Cocrystal Pharma Seeks Stockholder Approval for Key Corporate Governance Proposals at 2024 Annual Meeting

Cocrystal Pharma is holding its 2024 Annual Meeting of Stockholders virtually on June 25, 2024, to vote on key proposals including director elections, auditor ratification, and amendments to the Certificate of Incorporation.

Summary

• Cocrystal Pharma is convening its 2024 Annual Meeting of Stockholders on June 25, 2024, at 11:00 a.m. Eastern Time, accessible via audio conference call.
• Stockholders will vote on several key proposals, including the election of six directors for one-year terms.
• They will also consider ratifying the selection of Weinberg & Company as the company's independent registered public accounting firm for the year ending December 31, 2024.
• An amendment to the Certificate of Incorporation is proposed to reduce the authorized capital stock to 100 million shares of common stock and 1 million shares of preferred stock.
• Another proposed amendment seeks to limit the liability of the company's officers.
• Stockholders will also cast non-binding advisory votes on executive compensation and the frequency of future executive compensation votes.
• Additionally, they will vote on a proposal to allow for adjournment of the Annual Meeting if necessary to solicit additional proxies.
• The record date for determining stockholders entitled to vote at the Annual Meeting was April 29, 2024, with 10,173,790 shares of common stock outstanding and entitled to vote.
• The proxy materials were first mailed to stockholders on or about May 7, 2024.
• The Board of Directors recommends voting FOR Proposals 1, 2, 3, 4, 5, and 7, and for THREE YEARS on Proposal 6.

Sentiment

Score: 6

Explanation: The document is primarily informational and procedural, with a neutral tone. The proposals are standard corporate governance matters, and the document does not contain significant positive or negative news.

Positives

• The proposed amendment to reduce authorized capital stock could decrease future Delaware franchise taxes by approximately 34%, assuming no changes in gross assets, shares outstanding, or Delaware's franchise tax rate.
• The proposed amendment to limit officer liability could aid in attracting and retaining qualified officers.
• The company is seeking to align corporate governance practices with stockholder interests through advisory votes on executive compensation.

Negatives

• The company is seeking approval to adjourn the Annual Meeting to a later date if there are not sufficient votes to approve any of the proposals, which could indicate potential challenges in securing stockholder support.
• The company has incurred net losses of $(17,984,000) in 2023 and $(38,837,000) in 2022.

Risks

• Failure to obtain a quorum at the Annual Meeting could necessitate adjournment and additional proxy solicitation efforts.
• If the selection of the independent registered public accounting firm is not ratified, the Audit Committee will consider its options, potentially leading to additional costs and disruptions.
• There is a risk that the proposed amendments to the Certificate of Incorporation may not be approved by stockholders.
• The company's reliance on key executives and directors presents a risk if they are unable or unwilling to continue serving in their roles.

Future Outlook

The company estimates that the Authorized Share Decrease will result in a decrease in future Delaware franchise taxes of approximately 34%.

Industry Context

Many Delaware corporations are adopting or expected to adopt exculpation clauses that limit the personal liability of officers in their certificates of incorporation similar to the proposed Limitation of Liability Amendment.

Comparison to Industry Standards

• The proxy statement includes information on director and executive compensation, which is standard practice for publicly traded companies.
• The proposals to amend the Certificate of Incorporation to reduce authorized capital and limit officer liability are common corporate governance measures.
• The company's approach to board diversity and risk oversight aligns with Nasdaq listing rules and SEC regulations.
• The company's compensation policies and practices are designed to attract and retain executives with the right skills and experience, which is a common goal in the pharmaceutical industry.

Corporate Governance

Legal Proceedings

• On September 7, 2018, the SEC filed a complaint against Dr. Philip Frost, a director and principal stockholder of the Company, a trust Dr. Frost controls and OPKO Health, Inc., a stockholder of the Company, of which Dr. Frost is the Chief Executive Officer, as well as other defendants named therein.
• On January 10, 2019, the District Court entered final judgments against these defendants on their consent without admitting or denying the allegations set forth in the complaint.
• Dr. Frost was permanently enjoined from violating a certain anti-fraud provision of the Securities Act of 1933, future violations of Section 13(d) of the Exchange Act and Rule 13d-1(a) thereunder and participating in penny stock offerings subject to certain exceptions.

Related Party Transactions

• On April 4, 2023, the Company entered into a Securities Purchase Agreement with two accredited investors including Frost Gamma Investments Trust, a trust in which Phillip Frost, M.D., a director of the Company, is the trustee whereby each purchaser purchased 1,015,229 shares of common stock at a price of $1.97 per share, or two equal $2,000,000 investments.
• The second purchaser was Fred Hassan, who several weeks later was appointed a director of the Company.

Stakeholder Impact

• Approval of the proposed amendments to the Certificate of Incorporation could benefit stockholders by reducing franchise tax expenses and potentially improving the company's ability to attract and retain qualified officers.
• The advisory votes on executive compensation allow stockholders to express their views on the company's pay practices.
• The election of directors will determine the leadership and oversight of the company's strategic direction.

Next Steps

• Stockholders are urged to vote their shares promptly via the Internet, by phone, or by mail.
• The company will file a Current Report on Form 8-K within four business days after the Annual Meeting to announce the voting results.

Key Dates

Keywords

proxy statement, annual meeting, stockholders, corporate governance, executive compensation, board of directors, certificate of incorporation, officer liability, auditor ratification, director election, Cocrystal Pharma